Dibotermin alfa
As of the edition of 20 October 2026, Dibotermin alfa is a protein: marketed, first approved in 2002 (EU); acts on ACVR1, ACVR2A and ACVR2B and 3 more.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2004
- Kind
- Protein
- Brand name
- Inductos
- First approved
- 9 September 2002 (EU)
- Approvals on record
- 2 in 2 regions
- Holder of the most recent approval
- Medtronic BioPharma Sàrl; 2 holders in all
- Registered trials
- 5, 0 stopped early
- Disease areas
- Mouth and teeth; Nutrition and metabolism; Blood and lymph; Bones, joints and muscles; Heart and blood vessels; Hormones
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 2 | 0 | 1 | 0 |
| Phase 1 | 1 | 0 | 0 | 0 |
| Phase 3 | 1 | 1 | 0 | 0 |
| Phase 4 | 1 | 1 | 0 | 0 |
| All trials | 5 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Medtronic | Applicant | 2002 to now |